IP Library Patent Application 12531367
Patent Application
App. No. 12/531,367

QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/531,367
Abstract

Specific quinoline derivatives are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component.

Claims (18)

1 . A compound selected from the group consisting of:

[3-(4-cyanobenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]acetic acid,

[3-(4-bromobenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]acetic acid,

[4-ethyl-8-fluoro-3-(4-methanesulfonylbenzyl)-2-methylquinolin-5-yloxy]acetic acid,

[2-ethyl-8-fluoro-3-(4-methanesulfonylbenzyl)-4-methylquinolin-5-yloxy]acetic acid,

[4-difluoromethoxy-2-ethyl-8-fluoro-3-(4-methoxycarbonylaminobenzyl)quinolin-5-yloxy]acetic acid,

[4-difluoromethoxy-2-ethyl-8-fluoro-3-(3-methanesulfonylbenzyl)quinolin-5-yloxy]acetic acid,

(S)-2-[3-(4-chlorobenzyl)-4-difluoromethoxy-2-ethyl-8-fluoroquinolin-5-yloxy]propionic acid,

{4-difluoromethoxy-2-ethyl-8-fluoro-3-[4-(1-hydroxy-1-methylethyl)benzyl]quinolin-5-yloxy}acetic acid,

[8-chloro-3-(4-cyanobenzyl)-4-difluoromethoxy-2-ethylquinolin-5-yloxy]acetic acid,

[8-chloro-3-(2-chloro-4-cyanobenzyl)-4-difluoromethoxy-2-ethylquinolin-5-yloxy]acetic acid,

[8-chloro-3-(4-cyanobenzyl)-2-difluoromethoxy-4-methylquinolin-5-yloxy]acetic acid,

[3-(4-cyanobenzyl)-2-difluoromethoxy-8-fluoro-4-methylquinolin-5-yloxy]acetic acid, and salts, N-oxides, hydrates and solvates thereof.

2 . (canceled)

3 . A pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier.

4 - 5 . (canceled)

6 . A method of treating a disease selected from asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, comprising administering to a patient suffering such disease an effective amount of a compound as claimed in claim 1 .

7 . The method, according to claim 6 , used for the treatment of psoriasis, atopic and non-atopic dermatitis Crohn's disease, ulcerative colitis, or irritable bowel disease.

Assignments (2)
CHANGE OF NAME Recorded Jun 30, 2010
From: ARGENTA ORAL THERAPEUTICS LIMITED
To: PULMAGEN THERAPEUTICS (ASTHMA) LIMITED
Reel/Frame 024614/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2010
From: CRAMP, MICHAEL COLIN; ARIENZO, ROSA; HYND, GEORGE; CRACKETT, PETER; GRIFFON, YANN; HARRISON, TREVOR KEITH; RAY, NICHOLAS CHARLES; FINCH, HARRY; MONTANA, JOHN GARY
To: ARGENTA ORAL THERAPEUTICS LIMITED
Reel/Frame 023947/0001 →